Navigation Links
Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
Date:10/14/2010

SEATTLE, Oct. 14 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced that the National Institute on Drug Abuse (NIDA) has provided an additional grant to fund clinical studies for the Company's Addiction program. This grant, which is for a total of approximately $3.6 million to be paid over a four-year period in equal amounts, will fund direct and indirect costs of Phase 2 clinical studies to be conducted by researchers at the New York State Psychiatric Institute (NYSPI). In Omeros' Addiction program, the Company is developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPARgamma) agonists for the prevention and treatment of addiction to substances of abuse, such as opioids, nicotine and alcohol, as well as other compulsive behaviors, including eating disorders. Data from earlier European pilot clinical studies and animal models of addiction have demonstrated a previously unknown link between PPARgamma and addiction disorders.

Earlier this year, Omeros announced that NIDA agreed to fund substantially all of the costs of a Phase 2 clinical study to be conducted by NYSPI researchers to evaluate a PPARgamma agonist for the treatment of addiction to prescription opioids. The NIDA support announced today will be used to fund additional Phase 2 clinical studies to evaluate the effect of a PPARgamma agonist in combination with other agents on the use of heroin and cigarettes.  These clinical studies will also be conducted at the NYSPI and will be led by the recipients of this grant award, Dr. Sandra D. Comer and Dr. Adam Bisaga. Omeros will have the right to reference the data obtained from these studies for subsequent submissions to the FDA and will retain all other rights in connection with its Addiction program.

"This latest grant from NIDA underscores the potential of our Addiction program to yield a
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Omeros Secures $40 Million Committed Equity Financing Facility
2. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
3. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
4. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
5. Omeros Commences Initial Public Offering of Common Stock
6. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
9. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
10. Omeros and BlueCrest Announce $20 Million Debt Facility
11. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  AsureQuality and Ubiquitome ... testing for applications in food and primary production ... powered real-time PCR device, the Freedom4. ... through to the supermarket shelf for producers, processors ... involvement in animal disease control and pest management ...
(Date:7/29/2015)... 29, 2015 Research ... addition of the "Global Biosimilars Market, 2015 ... The Global Biosimilars Market, 2015 - 2025, ... growing biosimilars market. With the blockbuster biologics losing ... costs, biosimilars are being viewed as viable substitutes ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) announced ... be released on Thursday, August 13, 2015, before the ... management will host a conference call to discuss the ... release outlining the financial results and business update will ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2
... Quest Diagnostics,Incorporated (NYSE: DGX ), the nation,s ... announced that its Board of,Directors declared a quarterly ... per share, payable on July 18, 2008, to ... Quest Diagnostics, Quest Diagnostics is the leading ...
... Systems announces,the successful development and operation of the ... development of its Monarch250(TM) proton,therapy system. This cyclotron ... cyclotrons at this high field strength can be ... the operating,magnetic field, Still River Systems is developing ...
... At the 14th International,Leksell Gamma Knife(R) Society ... neurosurgeons, radiation oncologists and other medical,specialists using ... and other,brain disorders convened at the historic ... meeting, 260 oral and poster presentations covered,treatment ...
Cached Biology Technology:Still River Systems Announces Operation of the World's Highest Magnetic Field Cyclotron 2Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada 2Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada 3
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... new mother counts her newborn's fingers and toes, she ... for baby's complete set of 20 digits. , ... fatty substance responsible for clogging arteries, Vanderbilt University Medical ... to an important developmental protein controls the development of ...
... study, the presence of caspase-12, which appears to modulate ... "vulnerability to bacterial infection and septic shock" while a ... suggests that caspase-12 antagonists could be a potentially useful ... immune disorders. , The study was published in ...
... household gelling agent in making jams and jellies, but ... instance, and may have a role in important biological ... disease. , Despite the importance of pectin as a ... have known relatively little about how this family of ...
Cached Biology News:Cholesterol gets 'thumbs up' for role in digit development 2Cholesterol gets 'thumbs up' for role in digit development 3Lack of a key enzyme dramatically increases resistance to sepsis 2Lack of a key enzyme dramatically increases resistance to sepsis 3Discovery of new molecular tools for biosynthesis could lead to advances in use of pectin 2Discovery of new molecular tools for biosynthesis could lead to advances in use of pectin 3
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
... filter (S37100, Photographic Filters for Fluorescent ... for black-and-white photography of gels stained ... stain, the safer ethidium bromide alternative. ... filter is identical to the SYPRO ...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
LAL Chromogenic Endpoint assay...
Biology Products: